[{"orgOrder":0,"company":"Dechra Pharmaceuticals Manufacturing","sponsor":"Kindred Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"5-HT2C receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Dechra Pharmaceuticals Manufacturing","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dechra Pharmaceuticals Manufacturing \/ Dechra Pharmaceuticals PLC","highestDevelopmentStatusID":"12","companyTruncated":"Dechra Pharmaceuticals Manufacturing \/ Dechra Pharmaceuticals PLC"}]

Find Clinical Drug Pipeline Developments & Deals by Dechra Pharmaceuticals Manufacturing

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $43.0 million

                          March 16, 2020

                          Lead Product(s) : Mirtazapine

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Recipient : Kindred Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Divestment

                          blank